Abbott has contributed to the $18m second tranche of diabetes management technology developer Bigfoot Biomedical's latest round.
US-based insulin technology developer Bigfoot Biomedical has closed a $55m series B round featuring medical product maker Abbott, increasing its overall funding to approximately $91m.
Abbott joined undisclosed new and existing investors to provide $18m, adding to the $37m first tranche co-led by Janus Capital Management and Quadrant Capital Advisors, which closed in December 2017.
Cormorant Asset Management, Senvest Capital, Senvest Management, Visionnaire Ventures, JDRF T1D Fund and T1D Exchange also contributed to the first tranche.
Bigfoot is working on…
